



## **C-RAD celebrates success in the UK - SGRT tender won at Northern Centers for Cancer Care**

**C-RAD has been announced as the vendor of choice and will supply cutting-edge SGRT (Surface Guided Radiation Therapy) solution to Northern Centers for Cancer Care in the UK. The agreement includes multiple Catalyst+ HD systems split across two sites: Freeman Hospital in Newcastle and Cumberland Infirmary in Carlisle.**

Northern Center for Cancer Care provide radiation oncology services to diagnose, treat and support people with cancer. The two centers in North England play a critical role in the cancer service across NHS north-east and west and will become strategic and important SGRT reference centers for C-RAD in the future. These two new sites join James Cook Hospital in Middlesbrough in offering to cancer patients in North England the latest C-RAD SGRT technology during their cancer treatment pathway.

Catalyst+ HD systems will be delivered with the complete software suite including modules for Respiratory Gating, Patient Setup & Positioning as well as Motion Monitoring. C-RAD SGRT technology provides the customer with a tool for accurate patient setup prior to the treatment and continuous monitoring of the patient during a treatment fraction. The technology enables accuracy and safety for the patient to support high precision treatment techniques -such as DIBH (Deep Inspiration Breath Hold)- as well as efficiency in a complex treatment workflow.

“We are thrilled to again be selected by this NHS trust and to be part of the important cancer care in the UK with our latest Surface Guided Radiation Therapy technology”, said Cecilia de Leeuw, CEO and President of C-RAD AB. “The UK is an important market for C-RAD and I am enthusiastic to see our customers choosing our technology, to help cancer patients receive the safest, most effective and accurate treatment possible.”

The total order has a value of approx. 7.8 MSEK which also includes a service contract for several years. Delivery and installation are expected to commence late 2023.

### **For further information:**

Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, [investors@c-rad.com](mailto:investors@c-rad.com)  
Christoffer Herou, CFO, +46 (0)725 82 86 16, [investors@c-rad.com](mailto:investors@c-rad.com)

Press Release  
01 November 2023 09:47:00 CET



## **About C-RAD**

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit <http://www.c-rad.com>

## **Attachments**

[C-RAD celebrates success in the UK - SGRT tender won at Northern Centers for Cancer Care](#)